Cognite Recognized as a Leader in Industrial Data Management Solutions
16.1.2025 15:59:00 CET | Business Wire | Press release
Independent Research Firm positions Cognite Data Fusion® as a market-leading DataOps and AI platform for enterprise-scale, complex industrial data management projects
Cognite, the global leader in AI for industry, today announced it has been named a Leader in the Verdantix Green Quadrant: Industrial Data Management Solutions 2025 report for providing a market-leading DataOps and AI platform for enterprise-scale, complex Industrial Data Management (IDM) projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114915194/en/
Verdantix Green Quadrant: Industrial Data Management Solutions 2025 (Graphic: Business Wire)
The report recognizes Cognite's platform, Cognite Data Fusion®, for its deeply configurable unstructured and structured industrial data orchestration, fast-paced product development, and world-class offering for complex asset-heavy industrial data and AI projects.
Cognite received a perfect score for its ‘data modeling’ capabilities, the foundational element of Cognite Data Fusion® that enables Cognite customers to adapt to emerging trends and stay ahead in a rapidly evolving technological climate. Additionally, Cognite received perfect scores across 'indirect industrial data acquisition,' 'platform development environment,' and 'platform APIs,' and the highest score for 'unstructured data utilization’ of all data platforms reviewed.
Verdantix also highlighted Cognite Atlas AI™ as an example of innovation in making industrial AI work for practical applications. With its focus on real-world usability, Cognite Atlas AI™ was called out for its ability to streamline agent-driven data retrieval and interpretation, supported by an industrial benchmarking report that helps organizations select the most suitable LLMs for their specific use cases.
“Industrial data management solutions play a critical role in enabling organizations to effectively integrate and leverage their data, particularly as AI becomes increasingly central to industrial operations,” said Joe Lamming, Senior Analyst, Industrial Transformation at Verdantix. “Cognite’s market-leading data modeling capabilities contextualize diverse data types, from structured time series to unstructured documents. We see such capabilities as vital for bridging the gap between raw data and actionable insights and automation. Solutions like those offered by Cognite show how industrial knowledge graphs can ground AI applications in domain-specific, cross-referenced truth, enabling organizations to build useful information systems in complex OT, IT, and ET environments.”
"Data modeling is the cornerstone of Cognite's approach to tackling complex industrial challenges," said Geir Engdahl, Chief Product Officer at Cognite. "Our advanced techniques, including our industrial agent workbench Cognite Atlas AI™, bridge the gap between raw data and actionable insights, making information accessible and meaningful to both humans and AI systems. As generative AI reshapes the industrial landscape, our commitment to robust and flexible data modeling ensures we empower customers with the right foundation for innovative AI-powered solutions tailored to their operational realities."
Cognite Data Fusion® serves as the cornerstone of Cosmo Energy's Digitalization (DX) aspirations," said Noriko Rzonca, Ph.D., Chief Digital Officer Cosmo Energy Holdings. “Generative AI-driven data modeling with Cognite empowers our operations to be safer and more optimized. We are thrilled to see them receive this well-deserved recognition as a leader in Industrial Management Solutions."
Read the full report here: Cognite recognized as a leader in Industrial Data Management solutions
Request a demo of Cognite Data Fusion® and Cognite Atlas AI™ here: cognite.com/request-demo
About Cognite
Cognite makes Generative AI work for industry. Leading energy, manufacturing, and power & renewables enterprises choose Cognite to deliver secure, trustworthy, and real-time data to transform their asset-heavy operations to be safer, more sustainable, and profitable. Cognite provides a user-friendly, secure, and scalable platform that makes it easy for all decision-makers, from the field to remote operations centers, to access and understand complex industrial data, collaborate in real-time, and build a better tomorrow. Visit us at www.cognite.ai and follow us on LinkedIn and X.
About Verdantix
Verdantix is the essential thought-leader for world-enhancing innovation. We support change-makers with our proprietary data, unique expertise and executive networks. Our impactful analysis is delivered via a digital platform, consulting engagements and in-person events to thousands of decision-makers in more than 100 countries. From offices in London, New York and Boston, the Verdantix research team applies the principles of rigour, accuracy and curiosity to help our globally distributed clients solve their most complex challenges. verdantix.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114915194/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom